Exact Sciences to Present Late-Breaking Data from Pivotal BLUE-C Study on Next-Generation Cologuard at ACG 2023

Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, has announced that it will be presenting late-breaking data from the pivotal BLUE-C study on next-generation Cologuard at the American College of Gastroenterology (ACG) Annual Meeting in Vancouver, Canada. The event is scheduled to take place from October 20-25, 2023.

The BLUE-C study, one of the largest colorectal cancer screening trials ever conducted, involved over 20,000 adults aged 40 and older. It aimed to evaluate the performance of next-generation Cologuard, which features novel biomarkers and improved laboratory processes. The study compared next-generation Cologuard with a fecal immunochemical test (FIT) using colonoscopy as a reference method.

During the ACG Annual Meeting, Exact Sciences will present three abstracts related to their research. The late-breaking data from the BLUE-C study will be presented by Thomas F. Imperiale, MD, the Principal Investigator of the BLUE-C study. The company will also present evidence supporting the cost-effectiveness and performance of next-generation Cologuard.

Exact Sciences will host information sessions at their booth, led by Paul Limburg, MD, MPH, AGAF, the Chief Medical Officer for Screening at Exact Sciences. These sessions will focus on the evidence presented at the Annual Meeting and will provide attendees with an opportunity to learn more about the advancements in colorectal cancer screening.

Next-generation Cologuard, developed in partnership with Mayo Clinic, has revolutionized colorectal cancer screening by offering a convenient and accurate testing option for those at average risk. The test has been used over 12 million times since its introduction almost a decade ago. Exact Sciences plans to release additional analyses of the BLUE-C data and complete its application to the FDA for approval of next-generation Cologuard in the coming months.

The Cologuard test is included in the colorectal cancer screening guidelines of the American Cancer Society, the U.S. Preventive Services Task Force, and the National Comprehensive Cancer Network. It is indicated for adults aged 45 and older who are at average risk for colorectal cancer.

Exact Sciences is committed to improving cancer screening and diagnostic tests to provide patients and healthcare professionals with the clarity needed to take life-changing action earlier. By investing in their pipeline, the company aims to develop innovative solutions for use before, during, and after a cancer diagnosis.

For more information about Exact Sciences and their products, visit their website or follow them on social media platforms such as Twitter, LinkedIn, and Facebook.